Back to mobile site

Upgrade Could Mean NxStage (NXTM) Decline Finally Over

October 10, 2012 7:50 AM EDT Send to a Friend
Wells Fargo upgraded NxStage Medical (NASDAQ: NXTM) from Underperform to Market Perform with a price target of $12 to $13 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login